Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Cross Juventas Investment Shows Gene Therapy Appetite

This article was originally published in PharmAsia News

Executive Summary

South Korea's Green Cross Holdings has invested in the clinical-stage U.S. biotech firm Juventas Therapeutics in a bid to diversify into the cell and gene therapy sector. Along with Posco Capital, Green Cross led a $7.5 million investment in the Cleveland-based company, which focuses on developing non-viral gene therapies to treat advanced cardiovascular diseases.

You may also be interested in...



Gene Therapy’s Roller Coaster Ride

With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.

Regenerative Medicine Finally Feels The Love

Investment in regenerative medicine has boomed over the past couple years, according to data presented at the Alliance for Regenerative Medicine's third annual Regen Med Investor Day, and all signs point to an even bigger year in 2015.

HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line

HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC088879

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel